SelectQuote, Inc. (SLQT) Stock Analysis and Metrics

Sector: Financial Services Industry: Insurance Brokers CIK: 0001794783

Market Cap 187.90 Mn

P/E 11.02

P/S 0.11

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 375.78 Mn

Revenue Growth (1y) (Qtr) 5.58

Add ratio to table...

About

SelectQuote, Inc. is a leading technology-enabled, direct-to-consumer distribution and engagement platform for selling insurance policies and healthcare services. The company operates through three primary business segments: Senior, Life and Auto & Home insurance distribution, and Healthcare Services. SelectQuote leverages over 40 years of data and proprietary artificial intelligence to optimize lead acquisition, agent routing, and customer lifecycle management, with a focus on maximizing the lifetime value of commissions. SelectQuote generates...

SelectQuote, Inc. is a leading technology-enabled, direct-to-consumer distribution and engagement platform for selling insurance policies and healthcare services. The company operates through three primary business segments: Senior, Life and Auto & Home insurance distribution, and Healthcare Services. SelectQuote leverages over 40 years of data and proprietary artificial intelligence to optimize lead acquisition, agent routing, and customer lifecycle management, with a focus on maximizing the lifetime value of commissions.

SelectQuote generates revenue primarily through commissions earned from insurance carrier partners for policies sold on their behalf. The company does not underwrite insurance policies and bears no underwriting risk, instead acting as a distributor that matches consumers with insurance products from its carrier partners. Revenue is also derived from its Healthcare Services segment, which offers pharmacy products, chronic care management, and health navigation services to consumers, particularly seniors, through its SelectRx, SelectPatient Management, and Healthcare Select platforms.

The company operates through the following segments: Senior, Life and Auto & Home insurance distribution, and Healthcare Services.

• Senior: This segment provides unbiased comparison shopping for Medicare Advantage and Medicare Supplement insurance plans, as well as prescription drug, dental, vision, hearing, and critical illness products. SelectQuote represents approximately 25 leading nationally-recognized insurance carrier partners, including those owned by UnitedHealthcare, Humana, Wellcare, and Aetna. In the year ended June 30, 2025, MA and MS plans accounted for 90% of approved Senior policies, with term life and final expense products making up the remainder.

• Life: This segment offers term life, final expense, critical illness, accidental death, and juvenile insurance products through unbiased comparison shopping. SelectQuote works with approximately 20 leading nationally-recognized insurance carrier partners, many of which have relationships exceeding 20 years. For the year ended June 30, 2025, term life policies accounted for 40% of new premium within the Life division, while final expense policies accounted for 60%.

• Auto & Home: This segment distributes homeowners, auto, dwelling fire, and other ancillary insurance products through unbiased comparison shopping. SelectQuote partners with approximately 20 leading nationally-recognized insurance carriers, including Safeco, Progressive, and Travelers. Homeowners and auto products represented 83% of new premium within the Auto & Home division for the year ended June 30, 2025, with dwelling fire and other products making up the rest.

• Healthcare Services: This segment offers pharmaceutical products and health-related services through SelectRx, Healthcare Select, and SelectPatient Management (SPM). SelectRx is a Patient-Centered Pharmacy Home TM accredited pharmacy providing essential prescription and over-the-counter medications, customized packaging, and medication therapy management. Healthcare Select engages customers through health risk and lifestyle assessments to offer personalized health-related products and services. SPM, launched in 2024 after the acquisition of a chronic care management platform, provides scalable, technology-enhanced services for patients with chronic conditions to help them navigate the care continuum.

SelectQuote holds a strong position in the insurance distribution industry as a pioneer of direct-to-consumer term life insurance exchange and a leader in leveraging technology for personalized consumer engagement. The company differentiates itself through its proprietary technology platform, which integrates AI-driven lead scoring, intelligent routing, and workflow optimization to maximize agent productivity and customer lifetime value. Key competitors include eHealth, Inc. and GoHealth, Inc., but SelectQuote maintains a competitive edge through its scale, data assets accumulated over four decades, and deep relationships with major insurance carriers such as UnitedHealthcare, Humana, Aetna, and Wellcare.

SelectQuote serves individual consumers seeking insurance and healthcare solutions, with a primary focus on seniors aged 65 and older. The company's customer base includes individuals shopping for Medicare Advantage and Supplement plans, life insurance, auto and home insurance, and healthcare services such as pharmacy fulfillment and chronic care management. Specific customer names are not disclosed in the filing, but the company engages directly with consumers through its direct-to-consumer model and partners with insurance carriers and healthcare providers to deliver its services.

Investment thesis

Bull case

SelectRx has accelerated its growth trajectory with a 26 percent year‑over‑year increase in revenue and a 17 percent rise in member count. The platform’s 30‑day medication strip and pharmacist review model has already led to a measurable 20 percent reduction in hospital days, a key metric for payers. These operational improvements translate directly into higher gross margins for the health care services segment, which currently commands a 1 percent adjusted EBITDA margin. As the pharmacy segment matures, the company is positioned to capture incremental revenue from new drug categories and enhanced MTM services, creating a durable upside that the market has not yet priced in.
The company’s three‑segment structure—Senior, Health Care Services, and Life—provides a natural hedge against cyclical swings in any single line of business. Senior policies generate high LTV commissions, while Health Care Services delivers a cash‑rich revenue stream that is largely independent of carrier commission cycles. The Life segment, though currently modest, offers a low‑cost platform that can be scaled with minimal capital outlay. This diversification reduces systemic risk exposure and improves overall earnings stability, a factor that has been underappreciated by market participants.
Agent productivity has improved by 12 percent relative to two years ago, while marketing spend per approved policy has remained stable at $326. This combination of higher output and efficient acquisition has driven the senior business to a near‑record 39 percent EBITDA margin, the fourth consecutive year above 30 percent. The CFO’s emphasis on operating cash flow growth—projected to rise 20 percent in 2026—underscores management’s focus on converting operating profitability into tangible shareholder value. The margin discipline achieved in a volatile Medicare Advantage landscape suggests a resilient business model that can withstand regulatory and carrier fluctuations.
Management’s announcement of a multiyear partnership with a major PBM has eliminated the pricing uncertainty that previously weighed on the health care services segment. The new agreement provides predictable reimbursement terms and increased visibility into drug pricing, effectively neutralizing the one‑time $20 million hit previously forecast. By locking in stable margin parameters, the company removes a significant tail risk from its earnings forecast, giving investors a clearer path to forecasted profitability. This contractual certainty is an undervalued catalyst that should be reflected in valuation multiples.
The 415 million dollar credit facility, extended to 2031, gives SelectQuote a debt maturities profile that aligns with its long‑term growth plans. The new facility reduces interest expense by up to 100 basis points, freeing capital that can be deployed toward high‑margin initiatives such as selective growth in SelectRx or targeted acquisitions. The improved balance sheet flexibility allows the company to maintain aggressive agent hiring or invest in technology upgrades without compromising liquidity, a defensive moat not fully captured by current market pricing.

SelectRx has accelerated its growth trajectory with a 26 percent year‑over‑year increase in revenue and a 17 percent rise in member count. The platform’s 30‑day medication strip and pharmacist review model has already led to a measurable 20 percent reduction in hospital days, a key metric for payers. These operational improvements translate directly into higher gross margins for the health care services segment, which currently commands a 1 percent adjusted EBITDA margin. As the pharmacy segment matures, the company is positioned to capture incremental revenue from new drug categories and enhanced MTM services, creating a durable upside that the market has not yet priced in.
The company’s three‑segment structure—Senior, Health Care Services, and Life—provides a natural hedge against cyclical swings in any single line of business. Senior policies generate high LTV commissions, while Health Care Services delivers a cash‑rich revenue stream that is largely independent of carrier commission cycles. The Life segment, though currently modest, offers a low‑cost platform that can be scaled with minimal capital outlay. This diversification reduces systemic risk exposure and improves overall earnings stability, a factor that has been underappreciated by market participants.
Agent productivity has improved by 12 percent relative to two years ago, while marketing spend per approved policy has remained stable at $326. This combination of higher output and efficient acquisition has driven the senior business to a near‑record 39 percent EBITDA margin, the fourth consecutive year above 30 percent. The CFO’s emphasis on operating cash flow growth—projected to rise 20 percent in 2026—underscores management’s focus on converting operating profitability into tangible shareholder value. The margin discipline achieved in a volatile Medicare Advantage landscape suggests a resilient business model that can withstand regulatory and carrier fluctuations.
Management’s announcement of a multiyear partnership with a major PBM has eliminated the pricing uncertainty that previously weighed on the health care services segment. The new agreement provides predictable reimbursement terms and increased visibility into drug pricing, effectively neutralizing the one‑time $20 million hit previously forecast. By locking in stable margin parameters, the company removes a significant tail risk from its earnings forecast, giving investors a clearer path to forecasted profitability. This contractual certainty is an undervalued catalyst that should be reflected in valuation multiples.
The 415 million dollar credit facility, extended to 2031, gives SelectQuote a debt maturities profile that aligns with its long‑term growth plans. The new facility reduces interest expense by up to 100 basis points, freeing capital that can be deployed toward high‑margin initiatives such as selective growth in SelectRx or targeted acquisitions. The improved balance sheet flexibility allows the company to maintain aggressive agent hiring or invest in technology upgrades without compromising liquidity, a defensive moat not fully captured by current market pricing.

Bear case

SelectQuote’s revenue and EBITDA are heavily reliant on a limited number of carrier partners, many of which have already demonstrated a willingness to reduce marketing budgets and impose headwinds. The carrier cut that lowered 2026 guidance by $20 million is a clear indicator of this concentration risk, and there is no evidence to suggest that other carriers will not follow suit. Should a similar action occur, the company’s growth trajectory could be severely hampered, creating a downward spiral in both revenue and profitability.
While the PBM agreement is presented as a one‑time stabilization measure, the company’s exposure to pharmacy reimbursement rates remains high. The health care services segment grew 26 percent in revenue, yet its adjusted EBITDA margin fell from 2 percent to a loss of 62 percent in the six‑month period, reflecting margin erosion from PBM headwinds. If reimbursement trends continue to deteriorate, the segment’s profitability could deteriorate further, undermining the company’s overall earnings profile.
The company reports a high rate of policy terminations—approximately 7 percent of in‑force policies—significantly above the historical average. This trend erodes the lifetime value of commissions and reduces the predictability of future cash flows. Even though the firm boasts a strong recapture rate, the persistent churn indicates that the market may not be fully priced for the long‑term decline in commission LTV.
Regulatory uncertainty looms large, particularly with the upcoming CMS advance rate notice and potential changes to Medicare Advantage reimbursement. The company’s management acknowledges that the advanced rates may not reflect rising utilization costs, implying that future adjustments could be unfavorable. A tightening of regulations could further compress margins across all segments, creating an adverse operating environment that management has not fully quantified.
Direct‑to‑consumer carriers are gaining traction, and some of SelectQuote’s carrier partners have already reduced marketing spend to encourage this shift. As carriers invest more heavily in digital channels, the company's traditional agent‑based model may face declining relevance, especially among tech‑savvy seniors. If the industry moves away from the broker‑mediated approach, SelectQuote could see a sharp decline in policy acquisition volumes, eroding its revenue base.

SelectQuote’s revenue and EBITDA are heavily reliant on a limited number of carrier partners, many of which have already demonstrated a willingness to reduce marketing budgets and impose headwinds. The carrier cut that lowered 2026 guidance by $20 million is a clear indicator of this concentration risk, and there is no evidence to suggest that other carriers will not follow suit. Should a similar action occur, the company’s growth trajectory could be severely hampered, creating a downward spiral in both revenue and profitability.
While the PBM agreement is presented as a one‑time stabilization measure, the company’s exposure to pharmacy reimbursement rates remains high. The health care services segment grew 26 percent in revenue, yet its adjusted EBITDA margin fell from 2 percent to a loss of 62 percent in the six‑month period, reflecting margin erosion from PBM headwinds. If reimbursement trends continue to deteriorate, the segment’s profitability could deteriorate further, undermining the company’s overall earnings profile.
The company reports a high rate of policy terminations—approximately 7 percent of in‑force policies—significantly above the historical average. This trend erodes the lifetime value of commissions and reduces the predictability of future cash flows. Even though the firm boasts a strong recapture rate, the persistent churn indicates that the market may not be fully priced for the long‑term decline in commission LTV.
Regulatory uncertainty looms large, particularly with the upcoming CMS advance rate notice and potential changes to Medicare Advantage reimbursement. The company’s management acknowledges that the advanced rates may not reflect rising utilization costs, implying that future adjustments could be unfavorable. A tightening of regulations could further compress margins across all segments, creating an adverse operating environment that management has not fully quantified.
Direct‑to‑consumer carriers are gaining traction, and some of SelectQuote’s carrier partners have already reduced marketing spend to encourage this shift. As carriers invest more heavily in digital channels, the company's traditional agent‑based model may face declining relevance, especially among tech‑savvy seniors. If the industry moves away from the broker‑mediated approach, SelectQuote could see a sharp decline in policy acquisition volumes, eroding its revenue base.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Insurance Brokers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MRSH	Marsh & Mclennan Companies, Inc.	79.42 Bn	20.41	2.89	20.60 Bn
2	AON	Aon plc	69.98 Bn	17.83	4.00	14.66 Bn
3	AJG	Arthur J. Gallagher & Co.	55.55 Bn	34.46	3.76	12.72 Bn
4	WTW	Willis Towers Watson Plc	24.71 Bn	14.47	2.49	6.30 Bn
5	BRO	Brown & Brown, Inc.	19.80 Bn	16.79	3.09	7.89 Bn
6	XHG	XChange TEC.INC	6.75 Bn	-63.74	131.54	0.00 Bn
7	NP	Neptune Insurance Holdings Inc.	4.00 Bn	120.46	25.74	0.23 Bn
8	CRVL	Corvel Corp	2.98 Bn	28.23	3.17	-

Research Tools

Developers

SelectQuote, Inc. (NYSE: SLQT)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

SelectQuote, Inc. (NYSE: SLQT)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password